New oral migraine drug, Amerge

March 1998

Glaxo is introducing their new oral migraine drug, Amerge.

Think of Amerge (naratriptan) as similar to oral Imitrex (sumatriptan)...except Amerge is longer-acting.

This means fewer recurrent headaches with Amerge than with Imitrex. About 40% of patients using Imitrex have recurrent headaches because of its short half-life.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Hear a lot more about homocysteine
Venastat to relieve leg swelling due to varicose veins
Singulair (montelukast) for asthma
Serevent is approved for treating chronic obstructive pulmonary disease (COPD)
Obesity & Weight Loss New obesity drug, Meridia
Cardiology New combination antihypertensive called Teczem
Cardiology Whether patients can still take erythromycin before dental procedures to prevent bacterial endocarditis
Neurology & Pain New oral migraine drug, Amerge
Neurology & Pain Tasmar (tolcapone) for Parkinson's
Women's Health New strength of Prempro
Women's Health Topical testosterone for libido
Gastroenterology PrevPac, a new kit for H. pylori
Diabetes Boxed warning about which patients shouldn't take metformin (Glucophage)
Diabetes Another new drug for type 2 diabetes, called Prandin (repaglinide)
STIs New STD treatment guidelines
Poison Prevention National Poison Prevention Week is this month

New oral migraine drug, Amerge

Practical advice for a better career, with unlimited access to CE

Table of Contents